In addition, high levels of fibrinogen-to-albumin ratio (FAR), a novel inflammation-based biomarker, are associated with poor outcomes in various cancers, including esophageal squamous cell carcinoma (ESCC), breast cancer, gallbladder cancer, and soft tissue sarcoma [8, 9]. Here, ALB is linked to breast carcinoma.